Loading…

An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease

Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients...

Full description

Saved in:
Bibliographic Details
Published in:BMC gastroenterology 2015-11, Vol.15 (162), p.163-163, Article 163
Main Authors: Yoshimura, Naoki, Yokoyama, Yoko, Matsuoka, Katsuyoshi, Takahashi, Hiroki, Iwakiri, Ryuichi, Yamamoto, Takayuki, Nakagawa, Tomoo, Fukuchi, Takumi, Motoya, Satoshi, Kunisaki, Reiko, Kato, Shingo, Hirai, Fumihito, Ishiguro, Yoh, Tanida, Satoshi, Hiraoka, Sakiko, Mitsuyama, Keiichi, Ishihara, Shunji, Tanaka, Shinji, Otaka, Michiro, Osada, Taro, Kagaya, Takashi, Suzuki, Yasuo, Nakase, Hiroshi, Hanai, Hiroyuki, Watanabe, Kenji, Kashiwagi, Nobuhito, Hibi, Toshifumi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD. In an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI) of 200 to 450 received intensive GMA, at two sessions per week (n = 55) or one session per week (n = 49). Clinical remission was defined as a CDAI score
ISSN:1471-230X
1471-230X
DOI:10.1186/s12876-015-0390-3